Physician perceptions of GLP-1 receptor agonists in the UK

Current Medical Research and Opinion

Volumn 32, Issue 5, 2016, Pages 857-864

  Matza, Louis S ^a   Curtis, Sarah E ^b   Jordan, Jessica B ^a   Adetunji, Omolara ^b   Martin, Sherry A ^b   Boye, Kristina S ^b  

^a EVIDERA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

GLP 1 receptor agonists; Physician perceptions; Practice patterns; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ARTICLE; DRUG COST; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREATITIS; PERCEPTION; PHYSICIAN; PRACTICE GUIDELINE; RISK FACTOR; UNITED KINGDOM; WEIGHT REDUCTION; AGONISTS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2;

DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PANCREATITIS;

EID: 84958542795     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2016.1147025     Document Type: Article

References (24)

1. Harris SB, Kapor J, Lank CN, et al. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician 2010;56:e418-24
2. Levin PA, Wei W, Zhou S, et al. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes. J Manag Care Spec Pharm 2014;20:501-12
3. Ziemer DC, Miller CD, Rhee MK, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ 2005;31:564-71
4. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-9
5. Shah BR, Hux JE, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005;28:600-6
6. Hayes RP, Fitzgerald JT, Jacober SJ. Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract 2008;62:860-8
7. Tan AM, Muthusamy L, Ng CC, et al. Initiation of insulin for type 2 diabetes mellitus patients: what are the issues? A qualitative study. Singapore Med J 2011;52:801-9
8. Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications 2007;21:220-6
9. Abu Hassan H, Tohid H, Mohd Amin R, et al. Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: A qualitative exploration. BMC Fam Pract 2013;14:164
10. Brod M, Kongso JH, Lessard S, Christensen TL. Psychological insulin resistance: patient beliefs and implications for diabetes management. Qual Life Res 2009;18:23-32
11. Funnell MM, Kruger DF, Spencer M. Self-management support for insulin therapy in type 2 diabetes. Diabetes Educ 2004;30:274-80
12. Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care 2005;28:2543-5
13. Visram H. Patient barriers to insulin use in multi-ethnic populations. Can J Diabetes 2013;37:202-4
14. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34:1247-58 e1222
15. Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: A review. Diabetes Metab Res Rev 2011;27:528-42
16. Hall GC, McMahon AD, Dain MP, et al. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabet Med 2013;30:681-6
17. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
18. NICE. Type 2 diabetes: The management of type 2 diabetes. NICE Clinical Guideline 87. London, UK, 2009, last modified December 2014:54
19. Tran L, Zielinski A, Roach AH, et al. The pharmacologic treatment of type 2 diabetes: injectable medications. Ann Pharmacother 2015;49(6):700-14
20. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: A review of head-to-head clinical studies. Ther Adv Endocrinol Metab 2015;6:19-28
21. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists. A review of their efficacy and tolerability. Diabetes Care 2011; 34(Suppl 2):S279-84
22. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-42
23. Reid TS. Practical use of glucagon-like peptide-1 receptor agonist therapy in primary care. Clin Diabetes 2013;31:148-57
24. Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-58